A clinical trial running in Portsmouth to evaluate a new blood test that aims to identify multiple cancers in their very early stages has now recruited over 450 patients.

The MODERNISED study is examining ground-breaking technology not currently being used in any other multi-cancer detection tests under investigation.

The test looks for signals in the blood that suggest the immune system is launching a response to the first signs of cancer developing and is also being evaluated to see if it can identify which type of cancer it is.

The trial is recruiting from five hospitals across Hampshire and Dorset, including at Portsmouth Hospitals University NHS Foundation Trust.

It’s being run by researchers from Southampton in partnership with the Southampton Clinical Trials Unit and biotech company Proteotype Diagnostics Ltd. It is funded by the National Institute for Health and Care Research (NIHR) Invention for Innovation (i4i) programme and the Office for Life Sciences,

Ian Robinson, a 72 year-old grandfather of five, is one of those who has taken part in the trial after he was diagnosed with colorectal cancer following routine screening.

“I was sent the NHS bowel cancer screening kit. I think I had done four of these, normally with a negative result, but the most recent one indicated that there was a chance of cancer which was confirmed with a colonoscopy. There were no symptoms, no pain, nothing, so you would never know until it was much more advanced and therefore much more difficult to treat.”

Ian was invited to take part in the MODERNISED study, which involves a short appointment where a blood sample is taken.

“Obviously the team here is helping me, so I’m delighted to participate and hopefully help improve the way things are done.”

“My mother died from cancer. I now have children and five grandchildren, so yes, research is absolutely vital. The more cancers that can be identified as early as possible, that can benefit future generations, then it’s obviously the right way to go.”

Approximately 385,000 new cancer cases are diagnosed every year in the UK*. But some cancers can be hard to detect in the very early stages of the disease when they have relatively few symptoms or symptoms that can be mistaken for other things.

“When cancers are diagnosed later, there are often fewer treatment options available to patients,” says Dr Victoria Goss, Associate Professor and Head of Early Diagnosis Research at the Southampton Clinical Trials Unit. “Detecting cancer early means that treatment can begin sooner, increasing the chances of successful outcomes for patients.

“Improving early diagnosis is therefore a priority for us as researchers and for the NHS. But currently there are only 4 screening programmes in the UK and screening is only for one cancer at a time, so we are aiming to develop simple tests that can potentially pick up the signs of multiple cancers, giving the best possible chance of early, successful treatment.”

The MODERNISED study is being led by Professor Andy Davies, Director of the Southampton Cancer Research UK and National Institute for Health and Care Research Experimental Cancer Medicine Centre.

“Most current research into multi-cancer blood tests is focused on detecting abnormal DNA that has been released into the blood stream by cancer cells,” says Professor Davies. “But this circulating tumor DNA cannot always be detected in the very early stages of cancer.”

“We are instead looking at levels of certain proteins found in blood. We know that even in the earliest stages of cancer, the body’s immune response can lead to higher levels of these proteins being released, and we believe these may be a good way to test for early signs of the disease”.

The trial will see samples taken from 1000 patients with newly diagnosed cancer who are currently being treated on the NHS**, as well as 350 control samples from patients with similar symptoms that are not cancer, and also healthy volunteers.

“Preliminary studies have already shown that our test, which is called ENLIGHTEN***, because it measures coloured light signatures from proteins, has high levels of accuracy for picking up cancer in its very early stages,” says Dr Emma Yates, co-founder and Chief Scientific Officer of Proteotype Diagnostics Ltd. “We are now working with Professor Davies and the team at the Southampton Clinical Trials Unit to test it in a much larger group of people to see whether it may be a useful early diagnostic tool.”

Ian Dickerson, from Hampshire, has twice been diagnosed with two different types of cancer, both of which were caught early.

“When you’re told that you have cancer, the bottom drops out of your world,” says Ian. “It is awful. I like to think of myself as a pragmatic person but when I was told, I did not know which way was up.

“But I’ve been very lucky. Because of my early diagnosis I have not had to have chemotherapy or radiotherapy. If you can get that early diagnosis and get that treatment, hopefully minimal treatment, then life can carry on. I have a good life, and I’m lucky to be able to live it.”

“It means everything to know that early diagnosis research is happening. I think it’s absolutely brilliant that we’re looking at early diagnosis for a range of cancers. The focus is often on the biggest cancers, but we’re now starting to look at early diagnosis for other cancers, as we should. I’m just an ordinary bloke and I’ve had two, apparently fairly rare cancers. It can happen to anyone and the earlier the diagnosis the better.”

Professor Mike Lewis, NIHR’s Scientific Director for Innovation, said: “We are proud to be funding this important trial in partnership with the Office for Life Sciences. This innovative test has the potential to improve early cancer detection simultaneously across a range of cancers, giving people a better chance of detection and then successful treatment. It’s a great example of how research is supporting the government’s mission to reduce the number of lives lost to the biggest killers.”